Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab in OA of Knee or Hip (FACT OA1)
NCT03161093Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of fasinumab in osteoarthritis (OA) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Change in WOMAC Pain Subscale Scores at 16 weeks and Change in WOMAC Physical Function Subscale Scores at 16 weeks. Started Aug 2017; status: completed.
02
Drugs
fasinumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03161093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161093.